DNA Sequencing Equipment and Services Markets, 3rd. Edition

Date: September 7, 2012
Pages: 180
Price:
US$ 3,995.00
License [?]:
Publisher: Kalorama Information
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: D4089180B2BEN
Leaflet:

Download PDF Leaflet

DNA Sequencing Equipment and Services Markets, 3rd. Edition
This report, DNA Sequencing Equipment and Services Markets, represents the third time Kalorama has detailed the market for DNA sequencing systems, as well as consumables used in sequencing and sequencing services. Much has changed since the last Kalorama edition of this report. More companies are offering sequencing services. The market was moving in a relatively linear manner for about two years in terms of competition, with no disruptive technologies or business models introduced. After a period of relative stability, the market has seen major developments in 2011 and 2012. The introductions of the Ion Torrent PGM, PacBio RS and MiSeq have changed the situation in the market, with more new technologies expected from Ion Torrent as well as Oxford Nanopore.

DNA sequencing can be defined as any biochemical method for determining the order of the nucleotide bases, adenine, guanine, cytosine, and thymine, (A,G,C,T) in a DNA nucleotide. DNA Sequencing has accelerated research and discovery, which created a brisk market for sequencing systems that perform this work. TXThe growing availability of vast amounts of annotated sequence data permits life science researchers to undertake a much wider range of experiments.As part of the report’s coverage, the following data is provided:
  • Current Market Estimate
  • Historical Market Data since 2006
  • Forecast to 2016
  • Review of Major Company Sequencing Products
  • The Status of Next Gen Systems
  • Clinical Applications vs. Research Applications in Sequencing
  • Litigation and Intellectual Property Developments
  • Deals in the Industry
  • Market Share of Major Players
  • Challenges and Strategic Recommendations
It is the beginning of a revolutionary time for the life sciences. Pricing changes, purchases by first-time users. Consortia, initiatives, a Groups have been organizing to sequence hundreds or thousands of individuals, species, tumors and the like in a short period of time – the 1,000 Genomes Project, the 1,001 Arabidopsis Project, and many others, many of which are covered in Chapter 2 – Trends. Longer-term, questions still remain for broad areas that are seen as large opportunities, such as disease prevention and diagnostics.

The market remains volatile, but some patterns have been stabilizing in recent years. The report uses primary and secondary research to present market watchers with an assessment of the marketplace in 2012. As part of its coverage, the report profiles the following companies:
  • 454 Life Sciences (Roche)
  • Complete Genomics
  • Illumina
  • Life Technologies
  • Pacific Biosciences
In the next five to ten years, the report details, any of the related areas could turn into home runs, or strikeouts, for sequencers and in general. The science is constantly evolving, and trends could work against DNA sequencers for some reason. Microarrays are still more cost-effective for GWAS, but given the trends in the science and the sequencing costs, it seems inevitable that will change. Further complicating things, somatic mutations, viral genome insertions, and epigenetic changes continue throughout life. The competition has been brutal as systems are constantly improved and new products are appearing with increasing frequency. Longer-term, new segments in diagnostics and industry are likely to open up further. The pharmaceutical industry is likely to be a growing segment, due to personalized medicine and other genomics-related projects.
CHAPTER ONE: EXECUTIVE SUMMARY

Introduction
  New Systems, Services Create Uncertainty
  A Period of Rapid Adoption, But Lower Prices
  Further Longer-Term Challenges
  Rapid Growth Overall, But Intense Competition
  Customers’ Research Models Evolving
  Established Next-Generation Systems Seeing Slowdown
Background
  Scope and Methodology
  Applications and Definitions
  Types of Samples
  DNA Sequencing Strategies

CHAPTER TWO: SEQUENCER MARKET TRENDS

Industry and Technology Trends
  Market Fragmenting Into Multiple Product Types and Applications
  Continual Improvements Expand Sequencer Market
  Acquisitions and Collaborations for New Technologies
  Patent Infringement, Other Legal Disputes
  Slow Path to Potentially Large Clinical Markets
  Spread of Targeted Enrichment, Sequence-Capture Products and Services
  Synergies Appearing Between Life Science Companies’ Products
  Consumer Genomics, Genetic Testing, Pharmacogenetics Still Entering Mainstream
NHGRI Funding, Budget, Periodic Strategic Planning
  NHGRI Shifts Funds from Centralized Sequencing Centers
  NHGRI White Paper #4: The Future of Genome Sequencing
Genome Projects and Consortia
  The Cancer Genome Atlas (TCGA) Project
  National Plant Genome Initiative
  NSF/USDA Microbial Genome Sequencing Program

CHAPTER THREE: DNA SEQUENCING SYSTEMS AND TECHNOLOGIES

454 Life Sciences (Roche)
  Genome Sequencer FLX, FLX+, Junior
  Illumina
  HiSeq, HiScan SQ, MiSeq, Genome Analyzer IIx
  Intelligent Biosystems (Qiagen)/Azco Biotech
  LI-COR Biosciences 4300
  Life Technologies/Applied Biosystems
  ABI Prism 310 Genetic Analyzer
  ABI Prism 3100-Avant Genetic Analyzer
  Applied Biosystems 3100 Genetic Analyzer
  Applied Biosystems 3130 Genetic Analyzer
  Applied Biosystems 3130xl Genetic Analyzer
  Applied Biosystems 3500 Genetic Analyzer
  Applied Biosystems 3730 DNA Analyzer
  Applied Biosystems 3730xl DNA Analyzer
  ABI SOLiD 4, 5500, 5500xl, 5500xl W Genetic Analyzers
  Ion Torrent Personal Genome Machine (PGM)
  Pacific Biosciences
  PacBio RS
  Technologies Under Development
  Introduction
  Human Microbiome Project Technology Development Awards

CHAPTER FOUR: SEQUENCING MARKET ANALYSIS

Revenues Forecast
Historical Revenues
Overall Market Forecast
Sequencing For a Clinical Purpose
  Roche
  ABI
  Illumina
  Affymetrix
  B.C. Cancer Agency
  Emory Genetics Lab
  Bacterial and Viral Applications for NGS
  eGenomics
  BGI
  Pacific Biosciences
  Clinical Sequencing vs. Research Sequencing Markets

CHAPTER FIVE: COMPETITIVE ANALYSIS

  Introduction
  Benchtop and Third-Generation Sequencers Bring Instability
  Second-, Third-Generation Battle Still Undefined, Unresolved
  Increased Flexibility with Purchasing
  ABI Capillary Electrophoresis Holds Onto Large Segment
  DNA Sequencer Market Shares
  Smaller Companies Experiencing Struggles
  Features and Strengths of Second-Generation Sequencers
  454 Life Sciences GS FLX–Strengths/Advantages
  454 Life Sciences GS FLX–Weaknesses/Disadvantages
  454 Life Sciences GS Junior–Strengths/Advantages
  454 Life Sciences GS Junior–Weaknesses/Disadvantages
  Applied Biosystems SOLiD–Strength/Advantages
  Applied Biosystems SOLiD–Weaknesses/Disadvantages
  Illumina HiSeq/HiScan SQ–Strength/Advantages
  Illumina HiSeq/HiScan SQ–Weaknesses/Disadvantages
  Illumina MiSeq - Strength/Advantages
  Illumina MiSeq-Weaknesses/Disadvantages
  Life Technologies PGM-Weaknesses/Disadvantages
  Pacific Biosciences PacBio RS-Strength/Advantages
  Pacific Biosciences PacBio RS-Weaknesses/Disadvantages

CHAPTER SIX: INTELLECTUAL PROPERTY AND LITIGATION

  Developments
  Helicos’ Patent Infringement Suit Against PacBio, Life Technologies, and Illumina
  Intelligent Bio-Systems and Columbia University Sue Illumina for Infringement
  Illumina’s Two Lawsuits Against Complete Genomics for Infringement
  Illumina Sues Life Technologies Over Ion Torrent Systems
  Class Action Shareholder Lawsuit Filed Against Pacific Biosciences
  Affymetrix Dismisses Suit Against Pacific Biosciences and Former Employees
  Life Technologies Defeats VisiGen Stakeholders After Arbitration
  Catalyst Assets Sues Life Technologies for Infringement
  Patent Interference Between Life Technologies and Pacific Biosciences
  Life Technologies and Illumina Dispute Over Amplification on Solid Surfaces
  LadaTech Sues Illumina Over DNA Amplification Patent
  Illumina Files ‘841 Patent Infringement Suit Against Affymetrix
  Affymetrix and Illumina Settle Case Over ‘243, ‘432, ‘531, ‘365, and ‘716
  Applied Biosystems and Illumina Claims and Counter-claims Over Sequencing-by-Ligation Both Unsuccessful
  Fluidigm and Applied Biosystems Agree to End Case
  Beckman Coulter and Applied Biosystems Settle Outstanding Legal Disputes
  Cepheid and Idaho Technology Settle Dispute Over PCR Patents
  Enzo Biochem Disputes CalTech Sequencing Patents
  Huang v. CalTech
  Applied Biosystems and Amersham plc (GE Healthcare) Settle Sequencing Patent Litigation
  Early ABI (Life Technologies) Patents

CHAPTER SEVEN: DEALS

  List of Deals in the Sequencing Industry

CHAPTER EIGHT: CORPORATE PROFILES

  454 Life Sciences (Roche)
  Complete Genomics
  Illumina
  Life Technologies
  Pacific Biosciences

CHAPTER NINE: CHALLENGES AND STRATEGIC RECOMMENDATIONS

  Market Challenges
  Fragmentation of Market Complicates Competition
  Lower System Prices and Higher Output Restrain Revenues
  Market Slowed by Data Analysis and Interpretation Bottleneck
  Clinical Applications Present Range of Requirements and Challenges
  Threat of New Entrants Despite Increasing Barrier
  Potential for Saturation in High-End Segments
  Services Experiencing High Growth, But Eating Into Tools Companies’ Revenues
  Pharmacogenomics, Personal and Consumer Genomics Slowed by Regulatory and Medical Dogma
  Biases at Multiple Levels Raise Issues of Standards, Quality Metrics
  Strategic Recommendations
  Intense Competition Requires Constant Innovation
  Balance Risks by Diversifying
  Prepare for Applications Opened by Decreasing Cost
  Address Growing International Demand
  Create User-Friendliness Through Tailored Software Tools
  Increase Value by Combining with Complementary Technology or Content
  Explore Demand in Expanding Routine Industry Segments
  Establish Early Connections With End-Users
  Move Towards Diagnostic Environment Requires Partnering

LIST OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY
  Figure 1-1: DNA Sequencer Revenues, 2001-2011
CHAPTER TWO: SEQUENCER MARKET TRENDS
  Table 2-1: NHGRI Budget by Year Including ARRA Supplement, 2006-2012
  Figure 2-1: NHGRI Budget including ARRA (2006-2012)
  Table 2-2: Est. NHGRI Budget by Mechanism, 2012 ($M)
  Figure 2-2: NHGRI Budget
  Table 2-3: NHGRI Budget by Activity, 2010-2012 ($thou)
  Figure 2-3: NHGRI Budget by Activity, 2012
  Table 2-4: NHGRI Funding, Large-Scale Sequencing Centers ‘07&’12
  Figure 2-4: NHGRI Funding, Large-Scale Sequencing Centers ‘07&’12
  Table 2-5: NHGRI Funding, Centers for Mendelian Genomics, 2012
  Figure 2-5: NHGRI Funding, Centers for Mendelian Genomics, 2012
  Table 2-6: NHGRI Clinical Sequencing Exploratory Research Awards, 2012
  Table 2-7: Fuge Funding Recipients
  Table 2-8: Plant Genome Comparative Sequencing Program (PGCSP) Awards, FY 2011
  Table 2-9: NSF / USDA Microbial Genome Sequencing Program Awards, 2008-2011
  Table 2-10 Other Initiatives and Consortia Using DNA Sequencing, 2012
CHAPTER THREE: DNA SEQUENCING SYSTEMS AND TECHNOLOGIES
  Table 3-1: DNA Sequencer Products/ Technologies, 2012
  Table 3-2: NIH Human Microbiome Project Technology Dev’t Awards, 2010
  Table 3-3: NHGRI $1,000 Genome Grant Awards, 2009
  Table 3-4: NHGRI $1,000 Genome Grant Awards, 2010
  Table 3-5: NHGRI $1,000 Genome Grant Awards, 2011
  Table 3-6: NHGRI Advanced Sequencing Technology Awardees, 2009
  Table 3-7: NHGRI Medical Sequencing Discovery Awards, 2009
  Table 3-8: NHGRI Understanding Genome Function Awards, 2009
  Table 3-9: NHGRI Population Genomics Awards, 2009
  Table 3-10: NHGRI Advanced Sequencing Technology Awardees, 2009
  Table 3-11: Other Initiatives and Consortia Supporting Technology Development, 2012
CHAPTER FOUR: SEQUENCING MARKET ANALYSIS
  Figure 4-1: Cost of Sequencing a Genome
  Table 4-1: Market Forecast by Segment (Systems, Consumables, Services) , 2011-2016
  Table 4-2: Sequencing Market Revenues Growth Rates by Segment, 2011-2016 (Systems, Consumables, Services)
  Table 4-3: Sequencer Equipment Market, 2001-2011 ($M)
  Table 4-4: Growth Rates, Sequencer Equipment Market, 2001-2011 ($M)
  Figure 4-3: Sequencer Equipment Market, 2001-2011 ($M)
  Figure 4-4: ABI Sequencing Revenues, Q3 2001 – Q3 2008
  Figure 4-5: ABI Sequencing Revenues, Focus on Q4 2004 – Q3 2008
  Figure 4-6: DNA Sequencer Market Forecast, 2011-2016:
  Figure 4-7: Breakout of DNA Sequencing Market by Application(Clinical vs. Research) 2011
  Figure 4-8: Breakout of DNA Sequencing Market by Application(Clinical vs. Research) 2016
CHAPTER FIVE: COMPETITIVE ANALYSIS
  Table 5-1: DNA Sequencer Market Shares
  Figure 5-1: DNA Sequencer Market Shares
  Figure 5-2: Pacific Biosciences Quarterly Revenues, 2011-2012 ($M)
  Figure 5-3: Complete Genomics Quarterly Revenues, 2010-2012 ($M)
  Table 5-2 Comparison of Sequencers’ Performance, mid-2012
CHAPTER SIX: INTELLECTUAL PROPERTY AND LITIGATION
  Table 6-1: Patents
CHAPTER SEVEN: DEALS
  Table 7-1: Deals in the Sequencer Market
Skip to top


Ask Your Question

DNA Sequencing Equipment and Services Markets, 3rd. Edition
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: